source
- Third patient dies in Chinese trial of RiboX Therapeutics' experimental genetic therapyA patient with an autoimmune disease died after receiving an experimental genetic medicine from RiboX Therapeutics, a Shanghai‑based biotech startup. The death marks the third fatality reported in…
- Biotech raises $820M to bring China-sourced immunology drug to market via reverse mergerA biotech company has secured $820 million in investor commitments this month to bring its immunology drug, developed in China, to public markets. The funding will be used to complete a reverse me…